NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
double-stranded small interfering RNA that causes degradation of aminolevulinate synthase 1 ( ALAS1 ) mRNA in hepatocytes through RNA interference, reducing the elevated levels of liver ALAS1 mRNA. This leads to reduced circulating levels of neurotoxic intermediates aminolevulinic acid (ALA) and…
Loss of Exclusivity
LOE Date
Oct 3, 2034
104 months away
Patent Expiry
Oct 3, 2034
Exclusivity Expiry
Nov 20, 2026